Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: A prospective cohort study

Gut

Volumn 65, Issue 10, 2015, Pages 1602-1610

  Timmer, Margriet R ^a   Martinez, Pierre ^b   Lau, Chiu T ^a   Westra, Wytske M ^a   Calpe, Silvia ^a   Rygiel, Agnieszka M ^a   Rosmolen, Wilda D ^a   Meijer, Sybren L ^a   Ten Kate, Fiebo J W ^a   Dijkgraaf, Marcel G W ^a   Mallant Hent, Rosalie C ^c   Naber, Anton H J ^c   Van Oijen, Arnoud H A M ^d   Baak, Lubbertus C ^e   Scholten, Pieter ^e   Böhmer, Clarisse J M ^f   Fockens, Paul ^a   Maley, Carlo C ^g   Graham, Trevor A ^b   Bergman, Jacques J G H M ^a   Krishnadath, Kausilia K ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Academic Medical Centre University of Amsterdam ^*  (Netherlands)

^d Medical Centre Alkmaar   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^f Department of Orthopaedic Surgery   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MYC PROTEIN; PROTEIN P16; PROTEIN P53;

ADULT; AGE; AGED; ANEUSOMY; ARTICLE; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 20Q; CHROMOSOMES AND CHROMOSOMAL PHENOMENA; COHORT ANALYSIS; CYTOLOGY; DISEASE EXACERBATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL DYSPLASIA; GENE LOSS; GENETIC MARKER; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; ONCOGENE MYC; ONCOGENE NEU; OUTCOME ASSESSMENT; PRECANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CHROMOSOMAL INSTABILITY; COMPLICATION; ENDOSCOPY; ESOPHAGUS; ESOPHAGUS TUMOR; GENETIC SCREENING; GENETICS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; AGE FACTORS; BARRETT ESOPHAGUS; CHROMOSOMAL INSTABILITY; COHORT STUDIES; DISEASE PROGRESSION; ENDOSCOPY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENES, MYC; GENES, P16; GENETIC MARKERS; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84932636390     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309642     Document Type: Article

References (31)

1. Spechler SJ, Souza RF. Barrett's Esophagus. N Engl J Med 2014;371:836-45.
2. American Gastroenterological AssociationSpechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140:1084-91.
3. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365:1375-83.
4. Sikkema M, de Jonge PJF, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: A systematic review and meta-Analysis. Clin Gastroenterol Hepatol 2010;8:235-44.
5. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010;105:1523-30.
6. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-Analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2013;11:1245-55.
7. Gordon LG, Mayne GC, Hirst NG, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrett's esophagus. Gastrointest Endosc 2014;79:242-56.e6.
8. Weaver JMJ, Ross-Innes CS, Shannon N, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014;46:837-43.
9. Bian Y-S, Osterheld M-C, Fontolliet C, et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002;122:1113-21.
10. Bird-Lieberman EL, Dunn JM, Coleman HG, et al. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 2012;143:927-35.e3.
11. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-And high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
12. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 2007;4:e67.
13. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
14. Rygiel AM, Milano F, Ten Kate FJ, et al. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-Adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2008;17:1380-5.
15. Rygiel AM, van Baal JWPM, Milano F, et al. Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer 2007;109:1980-8.
16. Li X, Galipeau PC, Paulson TG, et al. Temporal and spatial evolution of somatic chromosomal alterations: A case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila Pa) 2014;7:114-27.
17. Fritcher EGB, Brankley SM, Kipp BR, et al. A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol 2008;39:1128-35.
18. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: The Prague C & M criteria. Gastroenterology 2006;131:1392-9.
19. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42.
20. Wang KK, Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.
21. Potapov S, Schmid M, Adler W. survAUC: Estimators of prediction accuracy for time-To-event data. 2012. http://cran.r-project.org/web/packages/survAUC/index.html (accessed 28 May2014).
22. Ripley BD, Venables WN. Modern Applied Statistics with S. 4th edn. New York: Springer, 2002.
23. Aron Eklund. survplot: Plot survival curves with number-At-risk. 2012.
24. Jin Z, Cheng Y, Gu W, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009;69:4112-15.
25. Timmer MR, Brankley S, Gorospe EC, et al. Mo1895 how do experts from different continents compare in interpretation of fluorescence in situ hybridization for Barrett's esophagus? Gastroenterology 2013;144(Suppl 1):S-686-7.
26. Sikkema M, Looman CWN, Steyerberg EW, et al. Predictors for neoplastic progression in patients with Barrett's esophagus: A prospective cohort study. Am J Gastroenterol 2011;106:1231-8.
27. Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-Associated neoplastic progression and predicts progression risk. Oncogene 2005;24:4138-48.
28. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.
29. Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013;62:1676-83.
30. Wongsurawat VJ, Finley JC, Galipeau PC, et al. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2006;15:509-16.
31. Davelaar AL, Calpe S, Lau L, et al. Aberrant TP53 detected by combining immunohistochemistry and DNA-FISH improves Barrett's esophagus progression prediction: A prospective follow-up study. Genes Chromosomes Cancer 2015;54:82-90.